2008
DOI: 10.1016/j.jconrel.2007.10.009
|View full text |Cite
|
Sign up to set email alerts
|

Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: Active ingredient and mediator of drug release

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
45
0
4

Year Published

2010
2010
2024
2024

Publication Types

Select...
5
2
2

Relationship

1
8

Authors

Journals

citations
Cited by 75 publications
(49 citation statements)
references
References 34 publications
0
45
0
4
Order By: Relevance
“…[31][32][33][34] The ability of LTSL to release encapsulated drug was found to be superior to that of conventional DPPC-based thermosensitive liposomes from which the encapsulated drug is released relatively slowly. [33][34][35][36][37][38] Inclusion of ~10 mol% of the lysolipid, such as mono-stearoylsn-glycero-3-phosphatidylcholine (MSPC), produced significantly higher membrane permeability, with the highest permeability occurring at phase transition temperature which increased the encapsulated drug release. 36 The encapsulated drug could fast release from the thermosensitive liposomes during hyperthermia treatment in the vasculature of tumor tissues site.…”
Section: Introductionmentioning
confidence: 99%
“…[31][32][33][34] The ability of LTSL to release encapsulated drug was found to be superior to that of conventional DPPC-based thermosensitive liposomes from which the encapsulated drug is released relatively slowly. [33][34][35][36][37][38] Inclusion of ~10 mol% of the lysolipid, such as mono-stearoylsn-glycero-3-phosphatidylcholine (MSPC), produced significantly higher membrane permeability, with the highest permeability occurring at phase transition temperature which increased the encapsulated drug release. 36 The encapsulated drug could fast release from the thermosensitive liposomes during hyperthermia treatment in the vasculature of tumor tissues site.…”
Section: Introductionmentioning
confidence: 99%
“…51 Incorporation of 10% mol hexadecylphosphocholine (HePC; Figure 5A) into the membrane of DPPG 2 -TSL further increased the release rate of the encapsulated drug, similar to lyso-PC. 71 HePC is structurally related to lyso-PC, but has better chemical and metabolic stability, and is approved as a lipophilic drug for the treatment of skin metastasis in breast cancer and for leishmaniasis. The in vitro cytotoxicity of HePC in DPPG 2 -TSL was heat-inducible and stronger than that induced by micellar HePC, which did not respond to heat.…”
mentioning
confidence: 99%
“…The in vitro cytotoxicity of HePC in DPPG 2 -TSL was heat-inducible and stronger than that induced by micellar HePC, which did not respond to heat. 71 Limmer et al passively loaded gemcitabine into DPPG 2 -TSL, 28 and their pharmacokinetic studies in rats using gemcitabine 6 mg/kg body weight showed an initial plasma half-life of 0.53 hours for gemcitabine encapsulated in DPPG 2 -TSL, with a size of 109 nm. The plasma half-life was increased to 2.59 hours when the vesicle size was increased to 129 nm.…”
mentioning
confidence: 99%
“…No entanto, o tratamento antitumoral por via oral com miltefosina é dificuldado pela toxicidade gastrointestinal assim como a administração intravenosa leva a ação hemolítica, o que limita seu uso (LINDNER et al, 2008;FIEGL et al, 2008;SEIFERT et al, 2007;AGRESTA et al, 2003 A grande variação de incidência geográfica nas taxas de câncer de colo do útero reflete diferenças na disponibilidade de triagem, que permite a deteccção e remoção de lessões pré-cancerosas, e prevalência da infecção pelo virus do papiloma (HPV) (VACCARELLA et al, 2013;BRUNI et al, 2010;FORMAN et al, 2012 …”
Section: Lista De Abreviações E Siglasunclassified